YLYang-Jun Li

Yang-Jun Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yang-Jun Li has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Ping Wang

    Department of Ophthalmology, The Second Affiliated Hospital of Air Force Medical University, Xi’an, China

    4 shared publications
  • Qiong Zhang

    Department of Ophthalmology, The Second Affiliated Hospital of Air Force Medical University, Xi’an, China

    3 shared publications
  • Chen-Jun Guo

    Tangdu Hospital, Air Force Medical University

    2 shared publications
  • Chenjun Guo

    Department of Ophthalmology, The Second Affiliated Hospital of Air Force Medical University, Xi’an, China

    2 shared publications
  • Nan Ma

    Department of Ophthalmology, The Second Affiliated Hospital of Air Force Medical University, Xi’an, China

    2 shared publications
  • Ping Wang

    Department of Ophthalmology, Tangdu Hospital, Air Force Medical University, Xi’an, People’s Republic of China

    2 shared publications

Latest Publications

  • Evaluation of globe-preserving therapies in unilateral cT2/cT3 retinoblastoma: a multicentre study of 1566 eyes

    by Yiran Yao, Mingpeng Xu, Jie Yang, Yunhan Zhu, Yilin Yu, Minglei Han, Xiaoyu He, Zhenyu Xu, Yanping Han, Xinji Yang, et al.

    Aims: To evaluate survival, globe salvage and visual outcomes of globe-preserving treatment approaches in unilateral cT2 and cT3 retinoblastoma, with a focus on cT3 disease. Methods: This multicentre, retrospective cohort study enrolled 1566 treatment-naïve unilateral retinoblastoma eyes (870 clinical (c)T2, 696 cT3 by eighth American Joint Committee on Cancer clinical tumour, node, metastases staging) from 11 Chinese tertiary centres. Patients underwent intra-arterial chemotherapy, intravenous chemotherapy or primary enucleation. Outcomes were globe salvage, overall survival, metastasis-free survival, high-risk histopathological feature prevalence and vision-preserving rate (≥light perception (LP)). Results: In this multicentre cohort of 1566 eyes, the globe-salvage rate across cT2 and cT3 retinoblastoma was higher with intra-arterial chemotherapy than with intravenous chemotherapy. When stratified by cT3 subcategories, intra-arterial chemotherapy achieved significantly higher globe-salvage rates than intravenous chemotherapy in cT3b eyes (HR 3.65; 95% CI 1.91 to 6.98) and cT3c eyes (HR 4.02; 95% CI 2.79 to 5.80). In contrast, globe salvage did not differ between intra-arterial chemotherapy and intravenous chemotherapy in cT3d eyes. Overall survival and metastasis-free survival did not differ between intra-arterial chemotherapy and primary enucleation. Among eyes with cT3b or cT3c disease, 79.4% of eyes salvaged with intra-arterial chemotherapy and 65.0% of eyes salvaged with intravenous chemotherapy retained at least LP. Detected high-risk pathological features were not significantly different between eyes treated with intra-arterial chemotherapy and those undergoing primary enucleation in cT3b or cT3c disease. Among secondary enucleated eyes with cT3d disease, intra-arterial chemotherapy was associated with lower rates of choroidal invasion. Conclusion: Intra-arterial chemotherapy may enable globe salvage in cT3b/c retinoblastoma, whereas cT3d eyes continue to warrant prompt enucleation.

  • Open Access

    Tocilizumab for the management of corticosteroid-resistant GO combined with OMG: a case series

    by Chenjun Guo, Ping Wang, Shaobo Zhang, Qilin Cheng, Qiong Zhang, Nan Ma, Yangjun Li

    To highlight the safety and efficacy of tocilizumab (TCZ) in Graves’ ophthalmopathy (GO) combined with ocular myasthenia gravis (OMG) patients refractory to steroids and cholinesterase inhibitor (CEI). This was retrospective case series. We reviewed the health records of patients with GO combined with OMG, ten of whom were refractory to corticosteroids and CEI treatment and received intravenous injection of TCZ. Ten patients were treated with four injections of TCZ (intravenously, 8 mg per kilogram of body weight, once a month). We analyzed the efficacy and safety of TCZ treatment for this subset of patients with GO and OMG. The main outcomes including quality of life questionnaire in Graves’ orbitopathy (GO-QoL) score, Clinical Activity Score (CAS), Myasthenia Gravis Activities of Daily Living profile (MG-ADL) score, proptosis, diplopia and ptosis were assessed at 3 time points: “Baseline” (before the TCZ injection), “4th month” (after fourth time TCZ injection), “Follow up” (Last follow-up). Comparing parameters at 4th month vs. at baseline, all indicators improved at 4th month including GO-QoL score of visual functioning subscale (82.29 ± 13.71 vs. 35.98 ± 20.66, P < 0.001), GO-QoL score of the appearance subscale (80 ± 8.75 vs. 40.63 ± 17.95, P < 0.001), CAS (1.3 ± 0.46 vs. 4.5 ± 0.81, P < 0.001), MG-ADL (2.5 ± 1.56 vs. 5.11 ± 1.14, P < 0.001). Furthermore, proptosis decreased from 19.73 ± 2.84 to 17.93 ± 2.26 mm at 4th month (P < 0.0001). Diplopia and ptosis were also resolved at 4th month. After following up for a minimum of 11 months, the patients had no signs of relapse. In addition, we observed that all analyzed patients exhibited no significant drug reactions following the administration of TCZ. Tocilizumab maybe a useful therapeutic option in refractory GO coexisting with OMG. However, considering the limitation of a retrospective study, short follow up period and small sample size of this study, randomized controlled studies are needed to validate our results.


  • Open Access

    Surgical resection and orbital iodine-125 brachytherapy for orbital malignancy: a novel treatment for orbital lymphoma

    by Nan Ma, Ping Wang, Shaobo Zhang, Xiaona Ning, Chenjun Guo, Qiong Zhang, Qilin Cheng, Jinbo Zhao, Yangjun Li

    Objectives: Orbital lymphoma is one of the most common adult orbital malignancies, accounting for approximately 10% of all orbital tumors. This study aimed to analyze the effects of surgical resection and orbital iodine-125 brachytherapy implantation for orbital lymphoma. Patients and methods: This was a retrospective study. Clinical data of 10 patients were collected from October 2016 to November 2018 and followed up to March 2022. Patients underwent the primary surgery for maximal safe removal of the tumor. After a pathologic diagnosis of a primary orbital lymphoma was established, iodine-125 seed tubes were designed based on the tumor size and invasion range, and direct vision was placed into the nasolacrimal canal or/and under the orbital periosteum around the resection cavity during the secondary surgery. Then, follow-up data, including the general situation, ocular condition, and tumor recurrence, were recorded. Results: Of the 10 patients, the pathologic diagnoses included extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (6 cases), small lymphocytic lymphoma (1 case), mantle cell lymphoma (2 cases), and diffuse large B-cell lymphoma (1 case). The number of seeds implanted ranged from 16 to 40. The follow-up period ranged between 40 and 65 months. All patients in this study were alive and well had tumors that were completely controlled. No tumor recurrences or metastases occurred. Three patients had dry eye syndrome and two patients had abnormal facial sensation. No patient had radiodermatitis involving the skin around the eye, and no patient had radiation-related ophthalmopathy. Conclusions: Based on preliminary observations, iodine-125 brachytherapy implantation appeared to be a reasonable alternative to external irradiation for orbital lymphoma.


  • Open Access

    Rapamycin improves Graves’ orbitopathy by suppressing CD4+ cytotoxic T lymphocytes

    by Meng Zhang, Kelvin K.L. Chong, Zi-Yi Chen, Hui Guo, Yu-Feng Liu, Yong-Yong Kang, Yang-Jun Li, Ting-Ting Shi, Kenneth K.H. Lai, Ming-Qian He, et al.

    CD4 + cytotoxic T lymphocytes (CTLs) were recently implicated in immune-mediated inflammation and fibrosis progression of Graves’ orbitopathy (GO). However, little is known about therapeutic targeting of CD4 + CTLs. Herein, we studied the effect of rapamycin, an approved mTOR complex 1 (mTORC1) inhibitor, in a GO mouse model, in vitro, and in patients with refractory GO. In the adenovirus-induced model, rapamycin significantly decreased the incidence of GO. This was accompanied by the reduction of both CD4 + CTLs and the reduction of orbital inflammation, adipogenesis, and fibrosis. CD4 + CTLs from patients with active GO showed upregulation of the mTOR pathway, while rapamycin decreased their proportions and cytotoxic function. Low-dose rapamycin treatment substantially improved diplopia and the clinical activity score in steroid-refractory patients with GO. Single-cell RNA-Seq revealed that eye motility improvement was closely related to suppression of inflammation and chemotaxis in CD4 + CTLs. In conclusion, rapamycin is a promising treatment for CD4 + CTL-mediated inflammation and fibrosis in GO.


  • Open Access

    Tocilizumab for the Management of Glucocorticoid-Refractory Idiopathic Orbital Inflammation

    by Ping Wang, Chen-Jun Guo, Shao-Bo Zhang, Xiao-Na Ning, Dan Ma, Yang-Jun Li

    Background: To demonstrate the efficacy of the anti-interleukin-6 receptor monoclonal antibody tocilizumab in patients with glucocorticoid-refractory idiopathic orbital inflammation (IOI). Patients and Methods: A retrospective, observational case series study on 16 (10 females, 6 male) consecutive patients treated with TCZ for glucocorticoid-refractory IOI between September 2020 and January 2022. Median follow-up was 14.0±4.68 months (range, 9-24 months). The mean age of the patients was 34.5±9.93 years (range, 19-60 years), All patients had been treated with glucocorticoid but condition is repeatedly reactivated when steroid tapering for 0.5-3 years. Each patient underwent ophthalmological examinations, laboratory tests, CT/MRI of orbit, and received the initiated treatment with a monthly dose of 8 mg/kg TCZ for 2 to 6 cycles. TCZ was withdrawn due to low disease activity. Patient-reported outcomes, clinician-reported outcomes, and CT/MRI findings of the orbit after treatment were collected at the follow-up to assess the response. Results: Among the patients, 7 (44%) had myositis, 5 (31%) had diffuse IOI, 2 (13%) had dacryoadenitis, and 2 (13%) had anterior IOI. All patients (100%) had eyelid swelling and oppressive orbital pain, 12 (75%) had diplopia and ocular motility restriction, 9 (56%) had ptosis, and 1 (6%) had vision decline. After one treatment with TCZ, the eyelid swelling, ptosis, and orbital pain improved in all patients and completely relieved after all treatments. The average numeric pain rating scale score of all patients was 4.88±2.18 (range, 2-9) and dropped to 0 before and after TCZ treatment respectively (PConclusion: TCZ can reduce orbital pain, eyelid swelling, muscle enlarge, ocular motility limitation of glucocorticoid-refractory IOI. Treatment with TCZ appears to offer another therapeutic option in cases of recalcitrant or recurrent IOI in which conventional treatment fails or contraindications to intravenous glucocorticoid pulse therapy.

  • Open Access

    Iodine-125 interstitial brachytherapy after tumor excision: an alternative eye-sparing surgery for lacrimal gland carcinoma

    by Yang-Jun Li, Ping Wang, Shao-Bo Zhang, Xiao-Na Ning, Chen-Jun Guo, Qiong Zhang, Qi-Lin Cheng

    Background:To describe the preliminary suppressive effects of iodine 125 brachytherapy for malignant lacrimal gland tumors after excisionMethods:The study recruit 9 patients with lacrimal gland carcinoma from May 2017 to December 2020. All patients underwent eye sparing surgical tumor resection first and then received iodine 125 interstitial brachytherapy to prevent tumor recurrence. We look over whether tumor recurred or metastasized by detecting the visual function and CT/MRI/PET MRI of every patient.Results1 patient was lost visit. The median follow up period was 29 months of other 8 patients (range, 7 43 months). One patient experienced recurrence two years later but was free from local disease after iodine 125 seeds were implanted one more time. The vision of one female patient was lost due to the seeds moving to the optic nerve. In the remaining 6 patients the vision was no changed, and CT/MRI showed no tumor was recurrencedConclusions:Permanent iodine 125 strip implantation in the orbit can be used as an alternative eye sparing surgery for malignant lacrimal gland tumors after tumor excision. It can control tumor recurrence and maintenance of vision and good cosmesis.

  • Iodine-125 interstitial brachytherapy for malignant lacrimal sac tumours: an innovative technique

    by Ping Wang, Nan Ma, Shaobo Zhang, Xiaona Ning, Chenjun Guo, Qiong Zhang, Qilin Cheng, Yangjun Li

    Objectives Primary malignant tumours of the lacrimal sac are rare, surgery and radiotherapy may induce substantial side effects for patients. Here, this article reports an innovative technique of interstitial brachytherapy developed for the treatment of malignant lacrimal sac tumours. Patients and methods Four patients (male 3, female 1), with an average age of 52.7 years (range 41–72 years), were individually diagnosed with squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma and lymphoma. All patients received Iodine-125 interstitial brachytherapy after surgical resection for malignant lacrimal sac tumours. Visual function examination (vision, intraocular tension, fundus photography, fluorescein angiography, and optical coherence tomography) and CT/MRI/PET-MRI were performed to look for signs of recurrent tumours or metastasis. Results Four patients were followed for an average of 28 months (range, 23–37 months). All patients were free from local disease. Their visual function was normal, and CT/MRI did not reveal any tumour recurrence. Conclusions Iodine-125 interstitial brachytherapy can be used as an alternative to wide excision or exenteration of these tumours. There was good local control, reasonable maintenance of vision, and good cosmesis.


  • Open Access

    Metastatic retinoblastoma of the parotid and submandibular glands: a rare case report

    by Ping Wang, Yang-Jun Li, Shao-Bo Zhang, Qi-Lin Cheng, Qiong Zhang, Li-Sha He

    Retinoblastoma is the most common intraocular malignancy occurring in children. It can metastasize to the regional lymph nodes, central nervous system and distant organs usually the bones and bone marrow and very rarely to the soft tissue. Here, we report a case of unilateral retinoblastoma in a 4-year-old girl accompanied by a large metastasis of the parotid and submandibular glands that developed about 6 months previously and gradually increased in size 5 months after enucleation of the left eye. A 4-year-old girl with a history of unilateral retinoblastoma presented with a large, painful and worsening mass (about 20 × 23 cm) of the left side of the neck. Following surgery, the orbital tumour was completely resected, and the large tumour invasion range in the left side of the neck was not resected completely. Histopathological examination revealed retinoblastoma of the orbit and the parotid and submandibular glands. After chemotherapy and additional local radiotherapy on the parotid and submandibular glands, the tumour was inactive and stable. Delayed detection and inappropriate management contribute to poor outcomes. Fundus examinations, education regarding the early signs of RB, and optimization of the therapeutic strategy for RB may play important roles in ocular health.


  • Improvement of the laser-induced damage resistance of optical coatings in vacuum environments

    by Yangjun Li, Xiulan Ling, Gaowang, Yuanan Zhao, Xiaofeng Liu, Jianda Shao


  • Congenital orbital fibrosis associated with fibrosis of extraocular muscle

    by YangJun Li, Jing Han, Hong Yan, Jing Li, Dan Wang, Shuang Xu

    Congenital orbital fibrosis is a non-familial, unilateral, distinct clinical entity, characterised by the presence of a diffusely infiltrating orbital mass and is extremely a rare disease. Congenital orbital fibrosis with combined fibrosis of extraocular muscles have not been reported previously. We treated an 8-year-old boy with the presence of a diffusely infiltrating orbital mass and fibrosis of extraocular muscles with secondary involvement of extraocular muscles. Clinical examination revealed left exotropia, hypotropia and fibrosis of extraocular muscle, an irregular, retrobulbar mass located within the orbit, incorporating the optic nerve, medial, superior, inferior and lateral rectus muscle. The CT, MRI and light microscopic studies confirmed the diagnosis. We performed exploration of the orbit, release and biopsy of scar tissue and strabismus surgery. Unlike other reported cases, our case was a progressive congenital disorder with combined fibrosis of extraocular muscle.